
Daniel Soffer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9727831/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment–Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. Circulation, 2019, 139, 1661-1670.	1.6	106
2	Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease. Circulation, 2018, 137, 2450-2462.	1.6	46
3	Effects of Methylnaltrexone on Ticagrelor-Induced Antiplatelet Effects inÂCoronary Artery Disease Patients Treated With Morphine. JACC: Cardiovascular Interventions, 2019, 12, 1538-1549.	2.9	26
4	Effects of Edoxaban on the Cellular and Protein Phase of Coagulation in Patients with Coronary Artery Disease on Dual Antiplatelet Therapy with Aspirin and Clopidogrel: Results of the EDOX-APT Study. Thrombosis and Haemostasis, 2020, 120, 083-093.	3.4	21
5	Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes. JACC Basic To Translational Science, 2020, 5, 419-428.	4.1	18
6	Pharmacodynamic Effects of VorapaxarÂin PatientsÂWith and WithoutÂDiabetes Mellitus. JACC Basic To Translational Science, 2019, 4, 763-775.	4.1	12
7	Pharmacodynamic and Pharmacokinetic Effects of a Low Maintenance Dose Ticagrelor Regimen Versus Standard Dose Clopidogrel in Diabetes Mellitus Patients Without Previous Major Cardiovascular Events Undergoing Elective Percutaneous Coronary Intervention. Circulation, 2020, 142, 1500-1502.	1.6	10
8	Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 728-737.	3.0	6
9	Pharmacodynamic Profiles of Dual-Pathway Inhibition with or without Clopidogrel versus Dual Antiplatelet Therapy in Patients with Atherosclerotic Disease. Thrombosis and Haemostasis, 2022, 122, 1341-1351.	3.4	5
10	Impact of chronic kidney disease on the pharmacodynamic and pharmacokinetic effects of ticagrelor in patients with diabetes mellitus and coronary artery disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 452-461.	3.0	2